Cargando…
Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China
OBJECTIVE: The study aims to quantify patients’ risk-benefit preferences for chemotherapy in the treatment of non-small cell lung cancer (NSCLC), and to elicit their willingness to pay (WTP) for treatment outcomes. METHODS: A face-to-face discrete choice experiment (DCE) was conducted on NSCLC patie...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790116/ https://www.ncbi.nlm.nih.gov/pubmed/31631985 http://dx.doi.org/10.2147/PPA.S224529 |
_version_ | 1783458746074136576 |
---|---|
author | Sun, Hui Wang, Huishan Xu, Ningze Li, Junling Shi, Jufang Zhou, Naitong Ni, Ming Hu, Xianzhi Chen, Yingyao |
author_facet | Sun, Hui Wang, Huishan Xu, Ningze Li, Junling Shi, Jufang Zhou, Naitong Ni, Ming Hu, Xianzhi Chen, Yingyao |
author_sort | Sun, Hui |
collection | PubMed |
description | OBJECTIVE: The study aims to quantify patients’ risk-benefit preferences for chemotherapy in the treatment of non-small cell lung cancer (NSCLC), and to elicit their willingness to pay (WTP) for treatment outcomes. METHODS: A face-to-face discrete choice experiment (DCE) was conducted on NSCLC patients in four tertiary hospitals each from Beijing, Shanghai, Guangzhou and Chengdu in China. Patients were invited to complete choice questions that constructed by seven attributes: progression-free survival (PFS), disease control rate (DCR), rash, nausea and vomiting, tiredness, mode of administration and out-of-pocket costs. A mixed logit model was used to evaluate the choice model. Estimates of relative preferences and marginal willingness to pay for each attribute were then explored. RESULTS: A total of 361 patients completed the survey. Improvements in PFS (10, 95% CI: 8.4–11.6) were the most important attribute for patients, followed by increase in DCR (4.6, 95% CI: 3.4–5.8). Tiredness (3.9, 95% CI: 2.9–5.1) was judged to be the most important risk. While remaining attributes were ranked in decreasing order of importance: nausea and vomiting (1.9, 95% CI: 0.9–3.0), mode of administration (0.8, 95% CI: 0.2–1.4) and rash (0.5, 95% CI: −0.6–1.5). There was little variation in preferences among patients with different sociodemographic characteristics. Patients were monthly willing to pay $2304 (95% CI, $1916–$2754) that guaranteed 11 months of PFS, followed by $1465 (95% CI, $1163-$1767) per month to improve their disease control rate by 90%. CONCLUSION: The results suggested that efficacy was the most important attribute for patients. Side effects, mode of administration and treatment cost significantly influenced patient preferences. Patient engagement in prioritizing their treatment preferences should be emphasized during the clinical decision-making process and regimen implementation. |
format | Online Article Text |
id | pubmed-6790116 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-67901162019-10-18 Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China Sun, Hui Wang, Huishan Xu, Ningze Li, Junling Shi, Jufang Zhou, Naitong Ni, Ming Hu, Xianzhi Chen, Yingyao Patient Prefer Adherence Original Research OBJECTIVE: The study aims to quantify patients’ risk-benefit preferences for chemotherapy in the treatment of non-small cell lung cancer (NSCLC), and to elicit their willingness to pay (WTP) for treatment outcomes. METHODS: A face-to-face discrete choice experiment (DCE) was conducted on NSCLC patients in four tertiary hospitals each from Beijing, Shanghai, Guangzhou and Chengdu in China. Patients were invited to complete choice questions that constructed by seven attributes: progression-free survival (PFS), disease control rate (DCR), rash, nausea and vomiting, tiredness, mode of administration and out-of-pocket costs. A mixed logit model was used to evaluate the choice model. Estimates of relative preferences and marginal willingness to pay for each attribute were then explored. RESULTS: A total of 361 patients completed the survey. Improvements in PFS (10, 95% CI: 8.4–11.6) were the most important attribute for patients, followed by increase in DCR (4.6, 95% CI: 3.4–5.8). Tiredness (3.9, 95% CI: 2.9–5.1) was judged to be the most important risk. While remaining attributes were ranked in decreasing order of importance: nausea and vomiting (1.9, 95% CI: 0.9–3.0), mode of administration (0.8, 95% CI: 0.2–1.4) and rash (0.5, 95% CI: −0.6–1.5). There was little variation in preferences among patients with different sociodemographic characteristics. Patients were monthly willing to pay $2304 (95% CI, $1916–$2754) that guaranteed 11 months of PFS, followed by $1465 (95% CI, $1163-$1767) per month to improve their disease control rate by 90%. CONCLUSION: The results suggested that efficacy was the most important attribute for patients. Side effects, mode of administration and treatment cost significantly influenced patient preferences. Patient engagement in prioritizing their treatment preferences should be emphasized during the clinical decision-making process and regimen implementation. Dove 2019-10-08 /pmc/articles/PMC6790116/ /pubmed/31631985 http://dx.doi.org/10.2147/PPA.S224529 Text en © 2019 Sun et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Sun, Hui Wang, Huishan Xu, Ningze Li, Junling Shi, Jufang Zhou, Naitong Ni, Ming Hu, Xianzhi Chen, Yingyao Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China |
title | Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China |
title_full | Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China |
title_fullStr | Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China |
title_full_unstemmed | Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China |
title_short | Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China |
title_sort | patient preferences for chemotherapy in the treatment of non-small cell lung cancer: a multicenter discrete choice experiment (dce) study in china |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790116/ https://www.ncbi.nlm.nih.gov/pubmed/31631985 http://dx.doi.org/10.2147/PPA.S224529 |
work_keys_str_mv | AT sunhui patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina AT wanghuishan patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina AT xuningze patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina AT lijunling patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina AT shijufang patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina AT zhounaitong patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina AT niming patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina AT huxianzhi patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina AT chenyingyao patientpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcanceramulticenterdiscretechoiceexperimentdcestudyinchina |